Were Analysts Bullish Nevro Corp. (NYSE:NVRO) This Week?

May 16, 2018 - By Darrin Black

Nevro Corp. (NYSE:NVRO) Ratings Coverage

Among 7 analysts covering Nevro (NYSE:NVRO), 4 have Buy rating, 0 Sell and 3 Hold. Therefore 57% are positive. Nevro has $110.0 highest and $83 lowest target. $94.80’s average target is 21.15% above currents $78.25 stock price. Nevro had 10 analyst reports since December 12, 2017 according to SRatingsIntel. BMO Capital Markets maintained the shares of NVRO in report on Tuesday, December 12 with “Buy” rating. Canaccord Genuity maintained Nevro Corp. (NYSE:NVRO) on Thursday, April 12 with “Buy” rating. Canaccord Genuity maintained Nevro Corp. (NYSE:NVRO) on Tuesday, January 16 with “Buy” rating. The stock has “Buy” rating by William Blair on Tuesday, January 23. As per Tuesday, May 8, the company rating was downgraded by Northland Capital. The stock of Nevro Corp. (NYSE:NVRO) has “Market Outperform” rating given on Tuesday, May 8 by JMP Securities. The stock of Nevro Corp. (NYSE:NVRO) earned “Hold” rating by Wells Fargo on Tuesday, May 8. The rating was maintained by Canaccord Genuity on Tuesday, May 8 with “Buy”. On Thursday, February 22 the stock rating was maintained by Canaccord Genuity with “Buy”. Below is a list of Nevro Corp. (NYSE:NVRO) latest ratings and price target changes.

08/05/2018 Broker: Canaccord Genuity Old Rating: Buy New Rating: Buy Old Target: $110 New Target: $102 Maintain
08/05/2018 Broker: Northland Capital Rating: Hold Downgrade
08/05/2018 Broker: JMP Securities Old Rating: Market Outperform New Rating: Market Outperform Old Target: $120 New Target: $105 Maintain
08/05/2018 Broker: Wells Fargo Rating: Hold New Target: $84.0000 Downgrade
12/04/2018 Broker: Canaccord Genuity Rating: Buy New Target: $110.0000 Maintain
04/04/2018 Broker: Goldman Sachs Rating: Neutral New Target: $83 Initiates Coverage On
22/02/2018 Broker: Canaccord Genuity Rating: Buy New Target: $110.0 Maintain
23/01/2018 Broker: William Blair Rating: Buy Maintain
16/01/2018 Broker: Canaccord Genuity Rating: Buy New Target: $110.0 Maintain
12/12/2017 Broker: BMO Capital Markets Rating: Buy New Target: $100.0 Maintain

The stock increased 2.27% or $1.74 during the last trading session, reaching $78.25. About 535,291 shares traded or 29.08% up from the average. Nevro Corp. (NYSE:NVRO) has declined 8.11% since May 16, 2017 and is downtrending. It has underperformed by 19.66% the S&P500.

Nevro Corp., a medical device company, focuses on providing products for the patients suffering from chronic pain in the United States and internationally. The company has market cap of $2.35 billion. It develops and commercializes the Senza spinal cord stimulation system, an evidence neuromodulation platform for the treatment of chronic pain. It currently has negative earnings. The firm sells its products through its direct sales force, and a network of sales agents and independent distributors.

More important recent Nevro Corp. (NYSE:NVRO) news were published by: Nasdaq.com which released: “Recent Analysis Shows Paycom Software, American Renal Associates, Knowles, Timken, Nevro, and Unisys Market …” on May 15, 2018, also Seekingalpha.com published article titled: “Nevro’s (NVRO) CEO Rami Elghandour on Q1 2018 Results – Earnings Call Transcript”, Prnewswire.com published: “Nevro Recognized as a “Best Place to Work” in the Bay Area” on May 14, 2018. More interesting news about Nevro Corp. (NYSE:NVRO) was released by: Streetinsider.com and their article: “After-Hours Stock Movers 05/07: (FRED) (VECO) (FN) Higher; (NVRO) (INWK) (HTZ) Lower (more…)” with publication date: May 07, 2018.

Nevro Corp. (NYSE:NVRO) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


WP Twitter Auto Publish Powered By : XYZScripts.com